# Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy

> **NCT00718536** · PHASE4 · COMPLETED · sponsor: **Germans Trias i Pujol Hospital** · enrollment: 15 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Addition of raltegravir 800 mg QD to HAART

## Key facts

- **NCT ID:** NCT00718536
- **Lead sponsor:** Germans Trias i Pujol Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2019-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00718536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00718536, "Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00718536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*